during the designated preimplementation period (2,118 patients treated). During the six months after the switch to insulin injector pens, there were four reports of wrongdrug errors (three errors during dispensing and one error during administration to the patient), all involving insulin detemir and insulin aspart pens; in addition, there was one reported wrong-time error associated with a sliding-scale order for insulin aspart. Total insulin product costs for the preimplementation and postimplementation periods were $124,181 and $60,655, respectively. Conclusion. Using an interchange program to support the use of insulin pens at a specialty clinic and hospital provided increased staff safety and cost savings.
Index terms:
Costs; Drug administration; Economics; Errors, medication; Hospitals; Insulin; Insulin aspart; Insulin detemir; Insulins; Needles Am J Health-Syst Pharm. 2011; 68:1349-52 A n insulin pen is an injection device prefilled with insulin. Use of insulin pens has been promoted as more cost-effective than vial-and-syringe delivery forms in hospital settings. [1] [2] [3] [4] [5] [6] Insulin pens have been pilot-tested in 30% of hospitals, 1 and their use is estimated to provide an average cost savings of $36 per patient per hospital stay. 2 In addition, pens may provide increased accuracy with small insulin doses, especially with the administration of <5 units. [3] [4] [5] Moreover, the safety profile of pen-injector insulin delivery appears to be similar to that of vialand-syringe insulin delivery. 2, 6 Despite the advantages of insulin pens, the Institute for Safe Medication Practices (ISMP) mentions several risks associated with pen usage.
1 Similar labeling of different pen types (e.g., Novolin 70/30 mix, Novolog 70/30 mix) could lead to errors. Poor visualization may occur during insulin pen use, leading to needle-stick injuries or causing insulin to leak from the injection site. With a wide variety of pen devices available, nurses and caregivers may use improper administration techniques and, consequently, deliver inaccurate doses. In addition, there is a risk of contamination if nurses use a pen cartridge as a multidose vial, withdrawing insulin from the vial with a syringe for administration to a single patient or multiple patients. 1 ISMP recommends that institutions take initiative to improve patient and staff safety through formulary measures to limit the variety of insulin pens available in an institution as a way to prevent mix-ups and promote staff education and competency with use of the devices. 1 This article discusses the safety and cost savings of an institution's interchange of insulin vials to insulin pens.
Interchange proposal and implementation
Mayo Clinic in Florida is a multidisciplinary specialty clinic with a 214-bed hospital. As of July 2009 (before the interchange program), the formulary included 16 insulin products: 8 preferred formulary products and 8 products with formulary restrictions. The stock of these products was primarily maintained as vials; insulin pens were ordered on occasion for patient training purposes. Due to concerns about the large number of insulin products available, the potential for confusion involving the products, and infection risks, it was standard practice to dispense insulin vials from the pharmacy in a patient-specific manner. Each patient received one vial of insulin. Regular insulin vials were maintained as floor stock for emergency use but were not to be used for routine patient doses. No other insulin was available as floor stock. Each patient-specific insulin vial was stored in the patient's medication bin.
A proposal for a program to switch from insulin vials to insulin pens was developed by the clinic's drug information center. The interchange to promote pen use had a threefold purpose: to improve staff safety by reducing needle sticks, to reduce waste by dispensing a smaller dosage form and reducing the number of insulin products available, and to provide cost savings to the institution.
For proposal development, the pertinent published literature was reviewed [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] and benchmarking was conducted with other Mayo Clinic campuses and local diabetes-care clinics. The interchange proposal entailed a 1:1 unit conversion from vial to injector pen for all subcutaneous insulin orders, with no change in the prescribed frequency of use. The interchange included eight products (Table 1) .
Cost-projections for the interchange proposal were calculated from purchasing data obtained from Cardinal Healthcare for the period May 1, 2008-April 30, 2009. It was assumed that one vial dispensed was equivalent to one pen dispensed and that one pen would provide an adequate supply of insulin during the patient's hospital stay. The projections indicated that the proposed interchange would yield estimated annual cost savings of approximately $80,000.
The proposal was endorsed by the clinic's endocrinology division and ultimately approved by the pharmacy and therapeutics committee in July 2009. System changes were made during August and September 2009 and included the revision of insulin orders within the computerizedprescriber-order-entry database, pharmacy database, medication stock, and insulin-needle stock. In addition, education of nursing staff, including an overview of insulin pen use and a hands-on demonstration, was conducted two weeks before implementation. Implementation was scheduled for late September 2009.
Interchange evaluation
An evaluation of the interchange and initial experience with insulin pen use was conducted using data for the first six months after implementation, October 2009-March 2010, and the same six-month period during the previous year.
The desired outcomes included a reduction in number of staff needlestick injuries and a reduction in pharmaceutical expenses during the postimplementation period. In addition, reported adverse drug reactions and patient incident reports involving insulin use were reviewed to provide information on patient safety. A review of the patient safety information was used to determine if the product interchange or the use of insulin pens had any negative impact on patient care.
Data on staff needle-stick injuries were obtained from employee incident reports. Insulin purchasing data included the number of purchased units and the cost of all insulin products purchased during the review periods. Table 2 presents data on the number of patients treated, insulin use and cost, and staff needle-stick injuries during the preimplementation and postimplementation periods. Data on the insulin purchased during the two periods are presented in Table 3 . The number of needle-stick injuries was lower after implementation of insulin pen use. The total cost of insulin products purchased was about $60,000 lower in the postimplementation period relative to the preimplementation period.
Results
Regarding patient safety, no adverse drug reaction reports involving insulin were received during either time period studied (Table 4) . Because the insulin interchange from vial to pen only applied to subcutaneous insulin doses, any reported errors during i.v. insulin therapy were not included in the analysis. (One incident report of "look-alike" packaging of two insulin pen products submitted during the postimplementation period also was not included, as the incident did not involve an error or near miss).
During the preimplementation period, there were six patient incident reports involving subcutaneous insulin use. Two of those errors reached patients (one error involved administration at the wrong time and the other involved administration to the wrong patient); both patients were monitored, and neither required treatment for hypoglycemia.
Of the patient incident reports received during the postimplementation period, four documented wrong-drug errors with insulin detemir and insulin aspart pens (three errors occurred during dispensing and one during administration). One reported wrong-time error was thought to be associated with the insulin aspart interchange for sliding- Insulin regular vials are used in the pharmacy for admixing insulin infusions and on patient care units as emergency stock.
c Products ordered as vials before implementation and as pens after implementation. d Although no orders were received, two vials were inadvertently procured but not dispensed.
e Orders received as "medically necessary, do not substitute"; products not interchanged per prescriber request. Table 4 . scale orders. The insulin sliding-scale order set was updated in response to this report to reflect the faster onset of action of insulin aspart compared with regular insulin. Five reported errors during the postimplementation period reached patients. Four of those errors were wrong-time errors. All patients involved were monitored; one patient required treatment with dextrose, and one patient was given orange juice. The other error that reached the patient involved a patient who was prescribed both insulin detemir and insulin aspart; the incorrect product was administered, potentially due to similar-looking pens. The patient was monitored but did not require treatment for hypoglycemia.
Insulin-Related Safety Reports

Discussion
Use of insulin pens pursuant to the insulin interchange was associated with a reduction in needle-stick injuries and cost savings for our institution. The needle-stick injury reported during the postimplementation period was potentially due to poor visualization of the needle. Furthermore, insulin expenses were reduced by approximately $60,000 over six months, primarily through the switch from vials of long-acting insulin products to the insulin detemir pen.
After data collection for this study, the pharmacy department was asked to review the number of insulin pen replacements dispensed to patients. Although some patients may require large doses of insulin, use of an insulin pen instead of a vial proved to be less expensive for our institution except in cases in which dispensing of a third pen was required. During October 2009, 689 pens were dispensed and out of that a total of 96 (14%) pens were dispenses of a second pen. No patients received more than 2 pens containing the same insulin product.
Our study had a few notable limitations. First, the study did not include a review of blood glucose response or insulin dose adjustments pursuant to blood glucose monitoring; that information would have helped to better characterize patient outcomes. Second, underreporting of adverse drug reactions or failure to submit incident reports could have occurred. Third, focused education on insulin pen use was provided, which may have increased awareness of the similarities of the pen products; as the study occurred soon after implementation, staff attention to the pen products may have been greater immediately after education and could diminish over time.
The improvements in staff safety achieved by the interchange program are maintained by ongoing training of newly hired staff in proper insulin pen use by the diabetes educator. With regard to patient safety, the pens dispensed are patient specific, and nurses are trained on the dangers of using pen cartridges as multidose vials for individual or multiple patients. In addition, there is no emergency floor stock of insulin pens; vials of regular insulin remain the only emergency floor stock of insulin provided in our institution.
To help ensure that patients receive appropriate insulin therapy at home, medication reconciliation is conducted at discharge. At that time, patients may be instructed to use the insulin product they were using before hospitalization or instructed to discontinue use of that product and use the product administered during the hospital stay.
Conclusion
Using an interchange program to support the use of insulin pens at a specialty clinic and hospital provided increased staff safety and cost savings.
